

# Chapter 225

## Dapsone

Joni G. Sago & Russell P. Hall III

### REFERENCES

1. Harvath L, Yancey KB, Katz SI: Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones. *J Immunol* **137**:1305, 1986
2. Debol SM, Herron MJ, Nelson RD: Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. *J Leukoc Biol* **62**:827, 1997
3. Maloff BL et al: Dapsone inhibits LTB<sub>4</sub> binding and bioresponse at the cellular and physiologic levels. *Eur J Pharmacol* **158**:85, 1988
4. Wozel G et al: Dapsone hydroxylamine inhibits the LTB<sub>4</sub>-induced chemotaxis of polymorphonuclear leukocytes into human skin: Results of a pilot study. *Inflamm Res* **46**:420, 1997
5. Wozel G, Lehmann B: Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes. *Skin Pharmacol* **8**:196, 1995
6. Thuong-Nguyen V et al: Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. *J Invest Dermatol* **100**:349, 1993
7. Coleman MD et al: Studies on the inhibitory effects of analogues of dapsone on neutrophil function in-vitro. *J Pharm Pharmacol* **49**:53, 1997
8. Schmidt E et al: The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. *Clin Exp Immunol* **124**:157, 2001
9. Abe M et al: A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha production from activated mononuclear cells on cutaneous lupus erythematosus. *Clin Exp Dermatol* **33**(6):759-763, 2008
10. Stendahl O, Dahlgren C: The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone; a possible mechanism in the treatment of dermatitis herpetiformis. *J Clin Invest* **62**:214, 1977
11. Kazmierowski JA et al: Dermatitis herpetiformis: effects of sulfones and sulfonamides on neutrophil myeloperoxidase-mediated iodination and cytotoxicity. *J Clin Immunol* **4**:55, 1984
12. Suda T et al: Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner. *Br J Dermatol* **152**:887, 2005
13. Lang PG: Sulfones and sulfonamides in dermatology today. *J Am Acad Dermatol* **1**:479, 1979
14. Zhu YI, Stiller MJ: Dapsone and sulfones in dermatology: Overview and update. *J Am Acad Dermatol* **45**:420, 2001
15. Holtzer CD, Flaherty JFJ, Coleman RL: Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxazole to dapsone. *Pharmacotherapy* **18**:831, 1998
16. Beumont MG et al: Safety of dapsone as *Pneumocystis carinii* pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. *Am J Med* **100**:611, 1996
17. Zuidema J, Hilbers-Modderman ESM, Merkus FWHM: Clinical pharmacokinetics of dapsone. *Clin Pharmacokinetics* **11**:299, 1986
18. Endre ZH et al: Successful treatment of acute dapsone intoxication using charcoal hemoperfusion. *Aust N Z J Med* **13**:509, 1983
19. Edstein MD et al: Excretion of chloroquine, dapsone and pyrimethamine in human milk. *Br J Clin Pharmacol* **22**:733, 1986
20. Sanders SW et al: Hemolytic anemia induced by dapsone transmitted through breast milk. *Ann Intern Med* **96**:465, 1982
21. Hocking DR: Neonatal haemolytic disease due to dapsone. *Med J Aust* **1**:1130, 1968
22. Maurus JN: Hansen's disease in pregnancy. *Obstet Gynecol* **52**:22, 1978
23. Collier PM, Kelly SE, Wojnarowska F: Linear IgA disease and pregnancy. *J Am Acad Dermatol* **30**:407, 1994
24. Draelos Z, Carter E, Maloney J et al: Two randomized studies demonstrate the efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris. *J Am Acad Dermatol* **56**:439.e1-10, 2007

25. Scheinfeld N: Aczone, a topical gel formulation of the antibacterial, anti-inflammatory dapsone for the treatment of acne. *Curr Opin Investigational Drugs* 10(5):474-481, 2009
26. Thiboutot D et al: Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. *Clin Pharmacokinet* 46(8):697-712, 2007
27. Stotland M, Shalita A, Kissling R: Dapsone 5% gel: A review of its efficacy and safety in the treatment of acne vulgaris. *Am J Clin Dermatol* 10(4):221-227, 2009
28. Piette W et al: Hematologic safety of dapsone gel 5% for topical treatment of acne vulgaris. *Arch Dermatol* 144(12):1564-1570, 2008
29. Lucky A et al: Dapsone gel 5% for the treatment of acne vulgaris: Safety and efficacy of long-term (1 year) treatment. *J Drugs Dermatol* 6(10):981-987, 2007
30. Ellard GA et al: Dapsone acetylation in dermatitis herpetiformis. *Br J Dermatol* 90:441, 1974
31. Ellard GA et al: Dapsone acetylation and the treatment of leprosy. *Nature* 239:159, 1972
32. Caraco Y, Wilkinson GR, Wood AJ: Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6 and 3A by omeprazole. *Clin Pharmacol Ther* 60:396, 1996
33. Gill JP, Gil Berglund E: CYP2C8 and antimalaria drug efficacy. *Pharmacogenomics* 8(2):187-198, 2007
34. Cucinell SA, Israili ZH, Dayton PG: Microsomal N-oxidation of dapsone as a cause of methemoglobin formation in human red cells. *Am J Trop Med Hygiene* 21:322, 1972
35. Hjelm M, DeVerdier CH: Biochemical effects of aromatic amines-I. Methaemoglobinaemia, haemolysis and Heinz-body formation induced by 4,4'-diaminodiphenylsulphone. *Biochem Pharmacol* 14:1119, 1965
36. Clement B et al: Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes. *Life Sci* 77:205, 2005
37. Ganesan S et al: Cytochrome P450-dependent toxicity of dapsone in human erythrocytes. *J Appl Toxicol* 2010 Apr;30(3):271-275. DOI: 10.1002/jat.1493, 2009
38. Eichelbaum M, Evert B: Influence of pharmacogenetics on drug disposition and response. *Clin Exp Pharmacol Physiol* 23:983, 1996
39. Roychowdhury S et al: Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes. *J Pharmacol Exp Ther* 314:43, 2005
40. Roychowdhury S et al: Detection of haptenated proteins in organotypic human skin explant cultures exposed to dapsone. *Drug Metab Disp* 35:1463-1465, 2007
41. Khan F et al: Effect of arylhydroxylamine metabolites of sulfamethoxazole and dapsone on stress signal expression in human keratinocytes. *J Pharm Exp Therap* 323(3):771-777, 2007
42. May DG et al: The disposition of dapsone in cirrhosis. *Clin Pharmacol Ther* 51:689, 1992
43. Goodwin CS, Sparell G: Inhibition of dapsone excretion by probenecid. *Lancet* 294:884, 1969
44. Lee BL et al: Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. *Ann Intern Med* 110:606, 1989
45. Balakrishnan SPS: Drug interactions—The influence of rifampicin and clofazimine on the urinary excretion of DDS. *Lepr India* 53:17, 1981
46. Coleman MD et al: The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. *Br J Clin Pharmacol* 34:244, 1992
47. Rhodes LE et al: Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. *Br J Dermatol* 132:257, 1995
48. Coleman M: Improvement of patient tolerance to dapsone: Current and future developments. *Dermatol Online J* 13(4):18, 2007
49. Mehta M: Cimetidine and dapsone-mediated methaemoglobinaemia. *Anaesthesia* 62:1188, 2007
50. Goolamali S, Macfarlane C: The use of cimetidine to reduce dapsone-dependent haematological side-effects in a patient with mucous membrane pemphigoid. *Clin Exp Dermatol* 34:e1025-e1026, 2009
51. Kruizinga EE, Hamminga H: Treatment of dermatitis herpetiformis with diaminodiphenylsulphone (DDS). *Dermatologica* 106:386, 1953
52. Katz SI: Treatment: drugs and diet, in dermatitis herpetiformis: The skin and the gut. *Ann Intern Med* 93:857, 1980

53. Katz SI et al: Erythema elevatum diutinum: Skin and systemic manifestations, immunologic studies, and successful treatment with dapsone. *Medicine (Baltimore)* **56**:443, 1977
54. Farley-Loftus R et al: Erythema elevatum diutinum. *Dermatology Online Journal* **14**(10):13, 2008
55. Leonard JN et al: Linear IgA disease in adults. *Br J Dermatol* **107**:301, 1982
56. Jablonska S et al: Linear IgA bullous dermatosis of childhood (chronic bullous dermatosis of childhood). *Clin Dermatol* **9**:393, 1992
57. Wojnarowska F et al: Chronic bullous disease of childhood, childhood cicatricial pemphigoid and linear IgA disease of adults: A comparative study demonstrating clinical and immunopathologic overlap. *J Am Acad Dermatol* **19**:792, 1988
58. Nanda A et al: Linear IgA bullous disease of childhood: An experience from Kuwait. *Ped Dermatol* **23**(5):442-447, 2006
59. Hall RP et al: Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. *Ann Intern Med* **97**:165, 1982
60. Callen JP: Treatment of cutaneous lesions in patients with lupus erythematosus. *Dermatol Clin* **12**:201, 1994
61. Raimer S et al: Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents. *Cutis* **81**:171-178, 2008
62. Fleischer A et al: Dapsone gel 5% in combination with dapalene Gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: A 12-Week, Randomized, Double-Blind Study. *J Drugs Dermatol* **9**(1):33-40, 2010
63. Dubina M, Fleischer A: Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide. *Arch Dermatol* **145**(9):1027-1029, 2009
64. Basset N et al: Dapsone as initial treatment in superficial pemphigus. Report of nine cases. *Arch Dermatol* **123**:783, 1987
65. Yasuda H et al: Subcorneal pustular dermatosis type of IgA pemphigus: Demonstration of auto-antibodies to desmocollin-1 and clinical review. [Review] [47 refs]. *Br J Dermatol* **143**:144, 2000
66. Heaphy MR et al: Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. *Arch Dermatol* **141**:699, 2005
67. Martin LK et al: The cochrane collaboration: interventions for pemphigus vulgaris and pemphigus foliaceus, <http://www.thecochranelibrary.com>, Issue 1, 2009
68. Gurcan H, Ahmed R: Efficacy of dapsone in the treatment of pemphigus and pemphigoid: Analysis of current data. *Am J Clin Dermatol* **10**(6):383-396, 2009
69. Person JR, Rogers RS: Bullous pemphigoid responding to sulfapyridine and the sulfones. *Arch Dermatol* **113**:610, 1977
70. Venning VA, Millard PR, Wojnarowska F: Dapsone as first line therapy for bullous pemphigoid. *Br J Dermatol* **120**:83, 1989
71. Bouscarat F et al: Treatment of bullous pemphigoid with dapsone: Retrospective study of thirty-six cases. *J Am Acad Dermatol* **34**:683, 1996
72. Schmidt E et al: Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: A retrospective study of 62 cases. *Cutis* **76**:205, 2005
73. Motegi S et al: Childhood bullous pemphigoid successfully treated with diaminodiphenyl sulfone. *J Dermatol* **32**:809-812, 2005
74. Kirtschig G et al: Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. *Arch Dermatol* **138**:380, 2002
75. Rogers RS, Mehregan DA: Dapsone therapy of cicatricial pemphigoid. [Review] [19 refs]. *Semin Dermatol* **7**:201, 1988
76. Miserocchi E et al: The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. *Ophthalmology* **109**:111, 2002
77. Cohen D et al: Childhood lichen planus pemphigoides: A case report and review of the literature. *Pediatr Dermatol* **26**(5):569-574, 2009
78. Cheng S et al: Subcorneal pustular dermatosis: 50 years on. *Clin Dermatol* **33**:229-233, 2007
79. Aram H: Acute febrile neutrophilic dermatosis (Sweet's syndrome). Response to dapsone. *Arch Dermatol* **120**:245, 1984
80. Walling HW et al: The relationship between neutrophilic dermatosis of the dorsal hands and Sweet syndrome: Report of 9 cases and comparison to atypical pyoderma gangrenosum. *Arch Dermatol* **142**:57, 2006
81. Cohen P: Neutrophilic dermatoses: A review of current treatment options. *Am J Clin Dermatol* **10**(5):301-312, 2009
82. Callen JP, Taylor WB: Pyoderma gangrenosum—A literature review. *Cutis* **21**:61, 1978

83. Teasley L, Foster C, Baltatzis S: Sclerokeratitis and facial skin lesions: A case report of pyoderma gangrenosum and its response to dapsone therapy. *Cornea* 26:215-219, 2007
84. Chang DJ et al: Dapsone in rheumatoid arthritis. [Review] [78 refs]. *Semin Arthritis Rheum* 25:390, 1996
85. Martin JA, Jarrett P: Rheumatoid papules treated with dapsone. *Clin Exp Dermatol* 29:387, 2004
86. Barranco VP, Minor DB, Soloman H: Treatment of relapsing polychondritis with dapsone. *Arch Dermatol* 112:1286, 1976
87. Damiani JM, Levine HL: Relapsing polychondritis—Report of ten cases. *Laryngoscope* 89(6 Pt 1):929-946, 1979
88. Callen JP: Treatment of cutaneous lesions in patients with lupus erythematosus. [Review] [41 refs]. *Dermatol Clin* 12:201, 1994
89. Walling H, Sontheimer R: Cutaneous lupus erythematosus: Issues in diagnosis and treatment. *Am J Clin Dermatol* 10(6):365-381, 2009
90. Ujiie H et al: Lupus erythematosus profundus successfully treated with dapsone: Review of the literature. *Arch Dermatol* 142:399, 2006
91. Guillevin L: Treatment of polyarteritis nodosa with dapsone. *Scand J Rheumatol* 15(1):95-96, 1986
92. Fortson JS et al: Hypocomplementemic urticarial vasculitis syndrome responsive to dapsone. *J Am Acad Dermatol* 15:1137, 1986
93. Iqbal H, Evans A: Dapsone therapy for Henoch-Schönlein purpura: A case series. *Arch Dis Child* 90:985, 2005
94. Shin J, Lee J, Chung K: Dapsone therapy for Henoch-Schonlein Purpura. *Arch Dis Child* 91(8):714, 2006
95. Fredenberg MF, Malkinson FD: Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. *J Am Acad Dermatol* 16:772, 1987
96. Sunderkötter C et al: Management of leukocytoclastic vasculitis. *J Dermatol Treatment* 16:193, 2005
97. Chen K, Carlson J: Clinical approach to cutaneous vasculitis. *Am J Clin Dermatol* 9(2):71-92, 2008
98. Sharquie KE: Suppression of Behçet's disease with dapsone. *Br J Dermatol* 110:493, 1984
99. Sharquie KE, Najim RA, Abu-Raghif AR: Dapsone in Behçet's disease: A double-blind, placebo-controlled, cross-over study. *J Dermatol* 29:267, 2002
100. Prendiville JS, Logan RA, Russell-Jones R: A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. *Clin Exp Dermatol* 13:67, 1988
101. Kaur M, Lewis H: Hidradenitis suppurativa treated with dapsone: A case series of five patients. *J Dermatol Treatment* 17:211-213, 2006
102. van de Kerkhof P: On the efficacy of dapsone in granuloma faciale. *Acta Derm Venereol* 74:61, 1994
103. Bolz S, Jappe U, Hartschuh W: Successful treatment of perifolliculitis capitis abscedens et sulfodiens with combined isotretinoin and dapsone. *J German Soc Dermatol* 6(1):44-47, 2007
104. Godeau B et al: Dapsone for chronic autoimmune thrombocytopenic purpura: A report of 66 cases. *Br J Haematol* 97:336, 1997
105. Damodar S et al: Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults—A report on 90 patients. *Eur J Haematol* 75:328, 2005
106. Damodar S et al: Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults—A report on 90 patients. *Eur J Haematol* 75(4):328-331, 2005
107. Cassano N et al: Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study. *Acta Dermato-Venereologica* 85:254, 2005
108. Criado R et al: Urticaria unresponsive to antihistaminic treatment: An open study of therapeutic options based on histopathologic features. *J Dermatol Treat* 19(2):92-96, 2008
109. Engin B, Ozdemir M: Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. *J Eur Acad Dermatol Venereol* 22(4):481-486, 2007
110. Letsinger JA, McCarty MA, Jorizzo JL: Complex aphthosis: A large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. *J Am Acad Dermatol* 52:500, 2005
111. Mimura M et al: Systemic treatment in severe cases of recurrent aphthous stomatitis: An open trial. *Clinics* 64(3):193-198, 2009
112. Lynde C, Bruce A, Rogers R: Successful treatment of complex aphthosis with colchicine and dapsone. *Arch Dermatol* 145(3):273-276, 2009
113. Steiner A, Pehamberger H, Wolff K: Sulfone treatment of granuloma annulare. *J Am Acad Dermatol* 13:1004, 1985

114. Cyr P: Diagnosis and management of granuloma annulare. *Am Fam Physician* **74**(10):1729-1734, 2006
115. Halverstam C, Lebwohl M: Nonstandard and off-label therapies for psoriasis. *Clin Dermatol* **26**(5):546-553, 2009
116. Rees R et al: The diagnosis and treatment of brown recluse spider bites. *Ann Emerg Med* **16**:945, 1987
117. Rees RS et al: Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision. *Ann Surg* **202**:659, 1985
118. Cole HP, Wesley RE, King LEJ: Brown recluse spider envenomation of the eyelid: An animal model. *Ophthal Plast Reconstr Surg* **11**:153, 1994
119. Elston DM et al: Comparison of colchicine, dapsone, triamcinolone, and diphenhydramine therapy for the treatment of brown recluse spider envenomation: A double-blind, controlled study in a rabbit model. *Arch Dermatol* **141**:595, 2005
120. Wright SW et al: Clinical presentation and outcome of brown recluse spider bite. *Ann Emerg Med* **30**:28, 1997
121. Mold JW, Thompson DM: Management of brown recluse spider bites in primary care. *J Am Board Fam Pract* **17**:347, 2004
122. Peterson MD: Brown spider envenomation. *Clin Tech Small Anim Pract* **21**(4):191-193, 2006
123. Tan J, Rao B: Mesotherapy-induced panniculitis treated with dapsone: Case report and review of reported adverse effects of mesotherapy. *J Cut Med Surg* **10**(2):92-95, 2006
124. Gokdemir G, Kucukunal A, Sakiz D: Cutaneous granulomatous reaction from mesotherapy. *Dermatol Surg* **35**(2):291-293, 2009
125. Sobjanek M et al: Successful treatment of Melkersson-Rosenthal syndrome with dapsone and triamcinolone injections. *J Eur Acad Dermatol Venereol* **22**(8):1029-1029, 2008
126. Smith L, Cox N: Dapsone treatment for eosinophilic fasciitis. *Arch Dermatol* **144**(7):845-847, 2008
127. Pittelkow MR, Smith KC, Su WP: Alpha-1-antitrypsin deficiency and panniculitis. Perspectives on disease relationship and replacement therapy. *Am J Med* **84**:80, 1988
128. Korver G, Liu C, Peterson M: Alpha-1-antitrypsin deficiency presenting with panniculitis and incidental discovery of chronic obstructive pulmonary disease. *Int J Dermatol* **46**(10):1078-1090, 2007
129. Lee S et al: Neutrophilic eccrine hidradenitis in non-small cell lung cancer. *Int J Dermatol* **46**(1):59-60, 2007
130. Ulmer A et al: Dapsone in the management of "insect bite-like reaction" in a patient with chronic lymphocytic leukemia. *B Jour Dermatol* **156**:163, 2007
131. Mahendran R, Grant JW, Norris PG: Dapsone-responsive persistent erythema multiforme. *Dermatology* **200**:281, 2000
132. Hoffman L, Hoffman M: Dapsone in the treatment of persistent erythema multiforme. *J Drugs Dermatol* **5**(4):375-377, 2006
133. Chan CC, Chu CY: Dapsone as a potential treatment for cutaneous Rosai-Dorfman disease with neutrophilic predominance. *Arch Dermatol* **142**:428, 2006
134. Chan C, Chu C: Dapsone as a potential treatment for cutaneous Rosai-Dorfman Disease with neutrophilic predominance. *Arch Dermatol* **142**(4):428-430, 2010
135. Gonzalez P et al: Idiopathic angioedema treated with dapsone. *Allergol et Immunopathol* **33**:54, 2005
136. Hall RP: Dapsone. In: *Comprehensive Dermatologic Drug Therapy*, edited by SE Wolverton. Philadelphia, W.B. Saunders Company, 2001, p. 230
137. DeGowin RL: A Review of the therapeutic and hemolytic effects of dapsone. *Arch Intern Med* **120**:242-248, 1967
138. Graham WR: Adverse effects of dapsone. *Int J Dermatol* **14**:494-500, 1975
139. Stroupe J et al: Adverse reactions associated with dapsone therapy in HIV-positive patients: A case presentation and review. *The AIDS Reader* **16**:47-48, 53-55, 2006
140. Hjelm M, DeVerdier CH: Biochemical effects of aromatic amines-I. Methaemoglobinaemia, haemolysis and Heinz-body formation induced by 4,4'-diaminodiphenylsulphone. *Biochem Pharmacol* **14**:1119, 1965
141. McMillan DC et al: Dapsone-induced hemolytic anemia: Effect of dapsone hydroxylamine on sulfhydryl status, membrane skeletal proteins and morphology of human and rat erythrocytes. *J Pharmacol Exp Ther* **274**:540, 1995
142. Jollow DJ, Bradshaw TP, McMillan DC: Dapsone-induced hemolytic anemia. *Drug Metab Rev* **27**:107, 1995

143. Cucinelli SA, Israili ZH, Dayton PG: Microsomal N-oxidation of dapsone as a cause of methemoglobin formation in human red cells. *Am J Trop Med Hygiene* **21**:322, 1972
144. McMillan DC et al: Lipids versus proteins as major targets of pro-oxidant, direct-acting hemolytic agents. *Toxicol Sci* **88**:274, 2005
145. Motulsky AG, Yoshida A, Stametoyannopoulos G: Variants of glucose-6-phosphate dehydrogenase. *Ann N Y Acad Sci* **179**:636, 1971
146. Wolverson S, Remlinger K: Suggested guidelines for patient monitoring: hepatic and hematologic toxicity attributable to systemic dermatologic drugs. *Dermatol Clin* **25**:195-102, 2007
147. Wertheim M et al: Dapsone induced haemolytic anaemia in patients treated for ocular cicatricial pemphigoid. *Br J Ophthalmol* **90**(4):516, 2006
148. Lee I et al: Complications related to dapsone use for pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant patients. *Am J Transplant* **5**:2791-2795, 2005
149. Naik P et al: Dapsone-induced hemolytic anemia in lung allograft recipients. *J Heart Lung Transplant* **27**:1198-1202, 2008
150. Flosadottir E, Bjarnason B: Full dapsone dose made possible by control of anaemia with darbepoetin-alpha. *Acta Derm Venereol* **88**:540-541, 2008
151. Mobacken H: Commentary to a paper by flosadottir & bjarnason on full dapsone dose made possible by control of anaemia with darepoetin-alpha. *Acta Derm Venereol* **88**:639, 2008
152. Coleman MD, Coleman NA: Drug-induced methaemoglobinaemia. Treatment issues. [Review] [84 refs]. *Drug Safety* **14**:394, 1996
153. Williams S et al: Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for *Pneumocystis carinii* pneumonia (PCP) prophylaxis: A correlation with cytochrome b5 reductase (CB5R) enzyme levels. *Pediatr Blood Cancer* **44**:55, 2005
154. Zosel A, Rychter K, Leikin J: Dapsone-induced methemoglobinemia: Case report and literature review. *Am J Therapeutics* **14**:585-587, 2007
155. Salamat A, Watson HG: Drug-induced methaemoglobinaemia presenting with angina following the use of dapsone. *Clin Lab Haem* **25**:327, 2003
156. Groeper K, Katcher K, Tobias JD: Anesthetic management of a patient with methemoglobinemia. *South Med J* **96**:504, 2003
157. Ashurst J et al: Pathophysiologic mechanisms, diagnosis, and management of dapsone-induced methemoglobinemia. *JAOA* **110**(1):18-20, 2010
158. Choi A, Sarang A: Drug-induced methaemoglobinaemia following elective coronary artery bypass grafting. *Anaesthesia* **62**:737-740, 2007
159. Orion E, Matz H, Wolf R: The life-threatening complications of dermatologic therapies. *Clin Dermatol* **23**:182-192, 2005
160. Rausch-Madison S, Mohsenifar Z: Methodologic problems encountered with cooximetry in methemoglobinemia. *Am J Med Sci* **314**:203-206, 1997
161. Coleman M, Taylor C: Effects of dihydrolipoic acid (DHLA),  $\alpha$ -lipoic acid, N-acetyl cysteine and ascorbate on xenobiotic-mediated methaemoglobin formation in human erythrocytes in vitro. *Env Toxicol Pharm* **14**(3):121-127, 2003
162. Ranawaka R et al: Dapsone-induced haemolytic anaemia, hepatitis and agranulocytosis in a leprosy patient with normal glucose-6-phosphate-dehydrogenase activity. *Lepr Rev* **79**:436-440, 2008
163. Teo R et al: Presumed dapsone-induced hypersensitivity syndrome causing reversible hypersensitivity myocarditis and thyrotoxicosis. *Ann Acad Med Singapore* **35**:833-836, 2006
164. Rao P, Lakshmi T: Increase in the incidence of dapsone hypersensitivity syndrome—An appraisal. *Lepr Rev* **72**:57-62, 2001
165. Alves-Rodrigues E et al: Dapsone syndrome with acute renal failure during leprosy treatment: Case report. **9**(1):84-86, 2005
166. Alves-Rodrigues EN et al: Renal hypersensitivity vasculitis associated with dapsone. *Am J Kidney Dis* **46**:E51, 2005
167. Tohyama M et al: Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. *Brit J Dermatol* **157**:934-940, 2007
168. Takahashi H et al: A case of drug-induced hypersensitivity syndrome showing transient immunosuppression before viral reactivation during treatment for pemphigus foliaceus. *Clin Exp Dermatol* **31**:33, 2006
169. Agrawal S, Agrawal A: Dapsone hypersensitivity syndrome: A clinico-epidemiological review. *J Dermatol* **32**:883, 2005
170. Frey HM et al: Fatal reaction to dapsone during treatment of leprosy. *Ann Intern Med* **94**:777, 1981
171. Prussick R, Shear NH: Dapsone hypersensitivity syndrome. *J Am Acad Dermatol* **35**:346, 1996

172. McKenna KE, Robinson J: The dapsone hypersensitivity syndrome occurring in a patient with dermatitis herpetiformis [letter]. *Br J Dermatol* 137:657, 1997
173. Leslie K et al: A near fatal case of the dapsone hypersensitivity syndrome in a patient with urticarial vasculitis. *Clin Exp Dermatol* 28:496-498, 2003
174. Kosseifi S et al: The dapsone hypersensitivity syndrome revisited: A potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. *J Occ Med Toxicology* 1:9, 2006
175. Johnson DA, Cattau EL Jr, Kuritsky JN: Liver involvement in the sulfone syndrome. *Arch Int Med* 46:875, 1986
176. Itha S et al: Dapsone induced cholangitis as a part of dapsone syndrome: A case report. *BMC Gastroenterol* 3:21, 2003
177. Dhanya N et al: Dapsone syndrome with leukemoid reaction. *Ind J Lepr* 78(4):359-363, 2006
178. Zhu K et al: Complete atrioventricular block associated with dapsone therapy: A rare complication of dapsone-induced hypersensitivity syndrome. *J Clin Pharm Therapeutics* 34:489-492, 2009
179. Higuchi M et al: A case of drug-induced hypersensitivity syndrome with multiple organ involvement treated with plasma exchange. *Ther Apheresis Dialysis* 9(5):412-416, 2005
180. Lawrence WA, Olsen HW, Nickles DJ: Dapsone hepatitis. *Arch Int Med* 147:175, 1987
181. Kingham JGC et al: Dapsone and severe hypoalbuminaemia. *Lancet* 2:662, 1979
182. Saqueton AC et al: Dapsone and peripheral motor neuropathy. *Arch Dermatol* 100:214, 1969
183. Daneshmend TK, Homeida M: Dapsone-induced optic atrophy and motor neuropathy. *BMJ Clin Res Ed* 283:311, 1981
184. Daneshmend TK: The neurotoxicity of dapsone. *Adv Drug React Ac Pois Rev* 3:43, 1984
185. Fine JD et al: Psychiatric reaction to dapsone and sulfapyridine [letter]. *J Am Acad Dermatol* 9:274, 1983
186. Gawkrödger D: Manic depression induced by dapsone in patient with dermatitis herpetiformis. *BMJ* 299:860, 1989
187. Daneshmend TK: Idiosyncratic dapsone induced manic depression. *BMJ* 299:324, 1989
188. Gopalani V, More A: Dapsone-induced acute myopia. *J Dermatol Venereol Leprol* 72:455-456, 2006
189. Chalioulias K et al: Anterior ischemic optic neuropathy associated with dapsone. *Eye* 20:943-945, 2006
190. Hornsten P, Keisu M, Wiholm BE: The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. *Arch Dermatol* 126:919, 1990
191. Andersohn F, Konzen C, Garbe E: Systematic review: Agranulocytosis induced by nonchemotherapy drugs. *Ann Intern Med* 146(9):167-165, 2007
192. Ognibene AJ: Agranulocytosis due to dapsone. *Ann Intern Med* 72:521, 1970
193. Potter MN et al: Agranulocytosis caused by dapsone therapy for granuloma annulare. *J Am Acad Dermatol* 20:87, 1989
194. Cockburn EM et al: Dapsone-induced agranulocytosis: Spontaneous reporting data [letter]. *Br J Dermatol* 128:702, 1993
195. Coleman MD: Dapsone-mediated agranulocytosis: Risks, possible mechanisms and prevention. *Toxicology* 162:53, 2001
196. Miyagawa S et al: Recombinant granulocyte colony-stimulating factor for dapsone-induced agranulocytosis in leukocytoclastic vasculitis. *J Am Acad Dermatol* 28:659, 1993
197. Borrás-Blasco J et al: Pure red cell aplasia associated with dapsone therapy. *Ann Pharmacother* 39:1137, 2005
198. Hiura Y et al: Hemophagocytic syndrome induced by diaminodiphenylsulfone. *J Dermatol* 34:730-731, 2007
199. Dawson AH, Whyte IM: Management of dapsone poisoning complicated by methaemoglobinemia. *Med Toxicol Adverse Drug Exp* 4:387, 1989
200. Shadnia S et al: Acute methemoglobinemia following attempted suicide by dapsone. *Arch Med Research* 37:410-414, 2006
201. Dawson AH, Whyte IM: Management of dapsone poisoning complicated by methaemoglobinemia. *Med Toxicol Adverse Drug Exp* 4:387, 1989
202. Ferguson J, Lavery G: Deliberate self-poisoning with dapsone—A case report and summary of relevant pharmacology and treatment. *Anaesthesia* 52:359-363, 1997
203. Kenner DJ et al: Permanent retinal damage following massive dapsone overdose. *Br J Ophthalmol* 64:741, 1980
204. Leonard JN et al: Dapsone and the retina [letter]. *Lancet* 1:453, 1982

205. Hussain N, Agrawal S: Optical coherence tomographic evaluation of macular infarction following dapsone overdose. *Ind J Ophthalmol* **54**(4):271-272, 2006
206. Thunga G et al: Effectiveness of hemodialysis in acute dapsone overdose—A case report. *Am J Emer Med* **26**:1070.e1-1070.e4, 2008
207. Clifton J, Leikin JB: Methylene blue. *Am J Ther* **10**:289, 2003
208. Prasad R et al: Dapsone induced methemoglobinemia: intermittent vs continuous intravenous methylene blue therapy. *Indian J Pediatr* **75**(3):245-247, 2008
209. Froud T et al: Dapsone-induced artifactual A1c reduction in islet transplant recipients. *Transplantation* **83**(6): 824-825, 2007
210. De D, Dogra S, Kaur I: Dapsone induced acute photosensitivity dermatitis: A case report and review of the literature. *Lepr Rev* **78**(4):401-404, 2007
211. Dipankar D, Dogra S, Kaur I: Dapsone induced acute photosensitivity dermatitis; a case report and review of literature. *Lepr Rev* **78**:401-404, 2007
212. Kar B: Dapsone-induced photosensitivity: A rare clinical presentation. *Photodermatol Photoimmunol Photomed* **24**(5):270-271, 2008